Dr. Mina Bissell has joined the Advisory Board at 3D bioprinter manufacturer CELLINK and will contribute to the company’s development within cancer research and focus on developing technologies advancing the field. The Iranian born scientist runs the Bissell Lab at Lawrence Berkeley National Laboratory and has been recognized for her lifetime contributions to the fields of breast cancer research, the enhanced role of extracellular matrix (ECM) and the nucleus environment to gene expression in normal and malignant tissues. These works have ushered and have changed some central paradigms that have strengthened the importance of context in the development of cancer.
In addition, she was named Distinguished Scientist, the highest rank bestowed at Lawrence Berkeley National Laboratory (LBNL), and serves as Senior Advisor to the Laboratory Director on Biology. She is also Faculty of four Graduate Groups in UC Berkeley: Comparative Biochemistry, Endocrinology, Molecular Toxicology, and Bioengineering (UCSF/UCB joint program).
Having challenged several established paradigms, Bissell is a pioneer in breast cancer research and her body of work has provided much impetus for the current recognition of the significant role that extracellular matrix (ECM) signaling and microenvironment play in gene expression regulation in both normal and malignant cells. Her laboratory developed novel 3D assays and techniques that demonstrate her signature phrase: after conception, “phenotype is dominant over genotype.”
As the company continues to enjoy rapid growth, the CELLINK advisory board now consist of 4 advisors who have covered and continue to cover highly relevant positions in the medical industry and academia. Rolf Claesson served as Chairman of Bayer HealthCare and Tecan Group, as well as CEO of Bayer Diagnostics. Dr. Ali Khademhosseini, served as Professor at Harvard-MIT, Brigham and Women’s Hospital and Harvard Medical School. Dr. David Williams is a Professor at Wake Forest School of Medicine and is regarded as a leading authority on biomaterials, medical devices, and biocompatibility. He authored and co-authored over 400 technical papers within his field of expertise.